ClinicalTrials.gg
CompletedNCT01734239Updated Oct 30, 2018Results posted

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

A Phase 3 interventional study of Pneumovax™ 23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections — 1 open to participants now, 1 under way, 1 of them phase 3. 23-valent pneumococcal capsular polysaccharide vaccine · Pneumococcal Infections.

Enrollment
13th of 15
102 · median 243
Started
2013
the only one that year
Phase 3
6 of 15
1 open now
Registered
5th of 15
by date
Lead sponsor
5 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 3, and was the 5th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 23-valent pneumococcal capsular polysaccharide vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for pneumococcal disease

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For participants 50 years of age or older: any underlying chronic illness must be in stable condition
  • For participants 2 to 49 years of age: participant has an increased risk for pneumococcal disease as a result of one of the following: chronic cardiovascular disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease, cerebrospinal fluid leaks, functional or anatomic asplenia, sickle cell anemia, living in a special environment or social setting such as crowded, closed communities
  • Male, or female not of , or female of reproductive potential who agrees to remain abstinent or to use 2 acceptable methods of through 6 weeks after study vaccination

Exclusion criteria

Exclusion Criteria:

  • Received prior vaccination with pneumococcal vaccine
  • Has known or suspected immune dysfunction or conditions associated with , or is receiving immunosuppressive chemotherapy, including long-term systemic
  • Has history of disease
  • Received a licensed within 3 months before or is scheduled within 3 months after study vaccination
  • Received a licensed inactivated vaccine within 28 days before or is scheduled within 28 days after study vaccination
  • Received an drug or other investigational vaccine within 2 months before or is scheduled within 28 days after study vaccination (3 months if a live virus vaccine)
  • Received any blood product or immunoglobulin preparation within 6 months before or 28 days after study vaccination
  • Hospitalized for acute illness within 3 months before study vaccination
  • Is a pregnant woman or nursing mother
  • History of invasive pneumococcal disease or of other culture-positive pneumococcal disease
  • History of fever illness within 3 days before study vaccination
  • Received antibiotic therapy for any acute illness within 7 days before study vaccination
  • to any components of the vaccine, including phenol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Pneumovax™ 23: Participants Between 2 and 49 Years

    Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1

    Biological: Pneumovax™ 23

  • Experimental
    Pneumovax™ 23: Participants >=50 Years

    Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1

    Biological: Pneumovax™ 23

Interventions

  • BiologicalPneumovax™ 23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F

    Also known as: V110

06

What researchers measure

Primary outcomes

  1. Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine

    Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays

    Time frame: Prevaccination and Day 28 after vaccination

  2. Percentage of Participants With >=2-fold Increase From Prevaccination to Postvaccination in Antibodies to Pneumococcal Serotypes Contained in the Vaccine

    Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. A \>=2-fold increase in serum antibody is a marker for serologic response to pneumococcal vaccination in adults.

    Time frame: Day 28 postvaccination

  3. Number of Participants With Elevated Body Temperature (>=37.6 °C Axillary / >=38.0 °C Oral or Equivalent)

    Time frame: Up to 5 days postvaccination

  4. Number of Participants Reporting an Injection-site or Systemic Adverse Experience That Was Reported by >=4 Participants

    An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site or systemic AEs that occurred in \>=4 participants were reported for this endpoint.

    Time frame: Up to Day 14 postvaccination

  5. Number of Participants Reporting Serious Adverse Experiences

    A serious AE (SAE) is an AE that 1) results in death, 2) is life threatening, 3) results in a persistent or significant disability or incapacity, 4) results in or prolongs an existing inpatient hospitalization, 5) is a congenital anomaly or birth defect, 6) is a cancer, 7) is an overdose, or 8) is another important medical event which, based on appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention

    Time frame: Up to Day 28 postvaccination

07

Results

Posted Sep 5, 2014

Participant flow

Participant flow — Overall Study
MilestonePneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 Years
Started5250
Completed5250
Not completed00

Outcome measures

PrimaryGeometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine

Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays

Time frame:
Prevaccination and Day 28 after vaccination
Reported as:
Mean · ug/mL
Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine
ug/mLPneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 Years
Serotype 1 prevaccination0.2 (0.2 to 0.3)0.2 (0.2 to 0.3)
Serotype 1 Day 28 postvaccination4.1 (3.0 to 5.4)2.5 (1.7 to 3.8)
Serotype 6B prevaccination0.5 (0.4 to 0.8)0.6 (0.5 to 0.8)
Serotype 6B Day 28 postvaccination2.7 (1.8 to 3.9)5.3 (3.4 to 8.5)
Serotype 14 prevaccination1.3 (0.8 to 2.0)3.6 (2.5 to 5.1)
Serotype 14 Day 28 postvaccination13.2 (8.7 to 20.1)32.7 (22.7 to 47.3)
Serotype 19F prevaccination1.5 (1.1 to 2.2)1.5 (1.1 to 2.1)
Serotype 19F Day 28 postvaccination12.6 (9.0 to 17.8)9.9 (7.0 to 14.1)
Serotype 23F prevaccination0.6 (0.4 to 1.0)1.1 (0.7 to 1.5)
Serotype 23F Day 28 postvaccination5.3 (3.6 to 7.7)8.1 (5.3 to 12.4)
PrimaryPercentage of Participants With >=2-fold Increase From Prevaccination to Postvaccination in Antibodies to Pneumococcal Serotypes Contained in the Vaccine

Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. A \>=2-fold increase in serum antibody is a marker for serologic response to pneumococcal vaccination in adults.

Time frame:
Day 28 postvaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With >=2-fold Increase From Prevaccination to Postvaccination in Antibodies to Pneumococcal Serotypes Contained in the Vaccine
Percentage of participantsPneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 Years
Serotype 196.2 (86.8 to 99.5)87.5 (74.8 to 95.3)
Serotype 6B76.9 (63.2 to 87.5)89.6 (77.3 to 96.5)
Serotype 1488.5 (76.6 to 95.6)89.6 (77.3 to 96.5)
Serotype 19F82.7 (69.7 to 91.8)79.2 (65.0 to 89.5)
Serotype 23F80.8 (67.5 to 90.4)87.5 (74.8 to 95.3)
PrimaryNumber of Participants With Elevated Body Temperature (>=37.6 °C Axillary / >=38.0 °C Oral or Equivalent)
Time frame:
Up to 5 days postvaccination
Reported as:
Number · Number of participants
Number of Participants With Elevated Body Temperature (>=37.6 °C Axillary / >=38.0 °C Oral or Equivalent)
Number of participantsPneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 Years
Number of Participants With Elevated Body Temperature (>=37.6 °C Axillary / >=38.0 °C Oral or Equivalent)10
PrimaryNumber of Participants Reporting an Injection-site or Systemic Adverse Experience That Was Reported by >=4 Participants

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site or systemic AEs that occurred in \>=4 participants were reported for this endpoint.

Time frame:
Up to Day 14 postvaccination
Reported as:
Number · Number of participants
Number of Participants Reporting an Injection-site or Systemic Adverse Experience That Was Reported by >=4 Participants
Number of participantsPneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 Years
Number of Participants Reporting an Injection-site or Systemic Adverse Experience That Was Reported by >=4 Participants165
PrimaryNumber of Participants Reporting Serious Adverse Experiences

A serious AE (SAE) is an AE that 1) results in death, 2) is life threatening, 3) results in a persistent or significant disability or incapacity, 4) results in or prolongs an existing inpatient hospitalization, 5) is a congenital anomaly or birth defect, 6) is a cancer, 7) is an overdose, or 8) is another important medical event which, based on appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention

Time frame:
Up to Day 28 postvaccination
Reported as:
Number · Number of participants
Number of Participants Reporting Serious Adverse Experiences
Number of participantsPneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 Years
Number of Participants Reporting Serious Adverse Experiences00

Adverse events

Collected over All adverse experiences were collected through Day 14 postvaccination; serious adverse experiences were collected through Day 28 postvaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pneumovax™ 23—0/102 (0%)14/102 (13.7%)
Most frequent other events
Most frequent other events
EventPneumovax™ 23
Injection site painGeneral disorders14/102

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 YearsTotal
Mean21.2 ± 15.360.4 ± 7.740.4 ± 23.1
Sex: Female, Male
Sex: Female, Male(Participants)Pneumovax™ 23: Participants Between 2 and 49 YearsPneumovax™ 23: Participants >=50 YearsTotal
Female162137
Male362965
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ciprero K, Zykov KA, Briko NI, Shekar T, Sterling TM, Bitieva E, Stek JE, Musey L. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Hum Vaccin Immunother. 2016 Aug 2;12(8):2142-2147. doi: 10.1080/21645515.2016.1165373. Epub 2016 May 5. PubMed 27149114 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Oct 2013, 4 months.

Results were first posted in Sep 2014, 10 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2012
First posted
Nov 27, 2012
StartActual
Jun 3, 2013
Primary completionActual
Oct 22, 2013
CompletionActual
Oct 22, 2013
Results first posted
Sep 5, 2014
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01734239
Responsible party
Sponsor
First posted
Nov 27, 2012
Start date
Jun 3, 2013
Primary completion
Oct 22, 2013
Completion
Oct 22, 2013
Results posted
Sep 5, 2014
Last update
Oct 30, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion